Filings buzz in pharmaceuticals: 3Q21 sees a 20% decrease in digitalization mentions
Mentions of digitalization within the filings of companies in the pharmaceutical industry fell 20% between the second and third quarters…
Dashboard Featured
-
-
Future of work hiring levels in the pharmaceutical industry rose in November 2021
The proportion of pharmaceutical companies hiring for future of work related positions rose in November 2021 compared with the equivalent…
-
Filings buzz in pharmaceuticals: 34% decrease in industrial automation mentions in Q2 of 2021
Mentions of industrial automation within the filings of companies in the pharmaceutical industry fell 34% between the first and second…
-
Pfizer acquires Amplyx Pharmaceuticals to advance anti-infectives pipeline
Pfizer has acquired US-based Amplyx Pharmaceuticals to advance its expertise in infectious disease and expand its anti-infectives pipeline. Amplyx focuses…
-
Science park merger creates UK’s largest life sciences ecosystem
US real estate investment company Harrison Street and UK real estate group Trinity Investment Management this week announced their joint…
-
Vertex and Obsidian enter agreement to develop gene-editing treatments
Vertex Pharmaceuticals (VRTX) and Obsidian Therapeutics have entered a strategic research partnership and licensing agreement to discover and develop novel…
-
Janux Therapeutics raises funding to advance T cell engager treatments
Janux Therapeutics has raised $125m through a series B funding round to advance its pipeline of next-generation T cell engager…
-
AZ’s proposed acquisition of rare disease-focused Alexion gets US clearance
AstraZeneca’s proposed $39bn acquisition of rare disease therapy company Alexion Pharmaceuticals has passed a US Federal Trade Commission (FTC) review.…
-
AstraZeneca gets US clearance for proposed Alexion acquisition
The US Federal Trade Commission (FTC) has granted clearance to AstraZeneca for its proposed acquisition of Alexion Pharmaceuticals for approximately…
-
Thermo Fisher to acquire clinical research company PPD for $17.4bn
Thermo Fisher Scientific (TFS) has announced a definitive agreement to acquire clinical research organisation PPD for $47.50 per share for…
